# US 2019/0315833 A1 · Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315833 A1
- Document ID: US20190315833A1
- Status: Published application
- Kind: A1
- Application number: 16/424,422
- Filed: 2019-05-28
- Published: 2019-10-17
- Earliest claimed: 2015-06-19
- Assignees: Immatics Biotechnologies GmbH
- Applicants: Immatics Biotechnologies GmbH
- Inventors: Andrea MAHR; Toni WEINSCHENK; Oliver SCHOOR; Jens FRITSCHE; Harpreet SINGH
- Web page: https://patentgrep.com/patent/US20190315833A1

## CPC

- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- A61K 35/15: Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K39/00)
- A61K 39/0011: {Cancer antigens}
- A61K 39/001111: {Immunoglobulin superfamily}
- A61K 39/001154: {Enzymes}
- A61K 39/001162: {Kinases, e.g. Raf or Src}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/42: Cancer antigens
- A61K 51/1027: {against receptors, cell-surface antigens or cell-surface determinants}
- A61K 51/1057: {the tumor cell being from liver or pancreas}
- A61P 35/00: Antineoplastic agents
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- C07K 16/303: {Liver or Pancreas}
- C12N 5/0636: {T lymphocytes}
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C12Q 1/6881: for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
- G01N 33/56977: {HLA or MHC typing}
- A61K 2039/572: {cytotoxic response}
- C07K 2317/72: Increased effector function due to an Fc-modification
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- C12N 2310/16: Aptamers
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- G01N 2333/70539: MHC-molecules, e.g. HLA-molecules
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

## Claims

### Claim 1

An expression vector expressing a nucleic acid encoding a peptide consisting of the amino acid sequence selected from SEQ ID NOs: 45, 46, 6, 1-5, 7-29, 31-44, 47-80, 82-98, and 100-161.

### Claim 2 (depends on 1)

A recombinant host cell comprising the expression vector of claim 1, wherein said host cell is a dendritic cell or a macrophage.

### Claim 3 (depends on 2)

A method for producing a peptide consisting of the amino acid sequence selected from SEQ ID NOs: 45, 46, 6, 1-5, 7-29, 31-44, 47-80, 82-98, and 100-161, comprising culturing the host cell of claim 2, and isolating the peptide from the host cell or its culture medium.

### Claim 4

An in vitro method for producing activated antigen-specific CD8+ cytotoxic T lymphocytes, comprising contacting in vitro T cells with antigen loaded human HLA-A*02 expressed on the surface of a suitable antigen-presenting cell or an artificial construct mimicking an antigen-presenting cell for a period of time sufficient to activate said T cells, wherein said antigen is a peptide consisting of the amino acid sequence selected from SEQ ID NOs: 45, 46, 6, 1-5, 7-29, 31-44, 47-80, 82-98, and 100-161.

### Claim 5 (depends on 4)

The method of claim 4, wherein the T cells are autologous to the patient.

### Claim 6 (depends on 4)

The method of claim 4, wherein the T cells are obtained from a healthy donor.

### Claim 7 (depends on 4)

The method of claim 4, wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.

### Claim 8 (depends on 4)

The method of claim 4, wherein the activated T cells are expanded in vitro.

### Claim 9 (depends on 4)

The method of claim 4, wherein the antigen presenting cell is infected with recombinant virus expressing the peptide.

### Claim 10 (depends on 9)

The method of claim 9, wherein the antigen presenting cell is a dendritic cell or a macrophage.

### Claim 11 (depends on 8)

The method of claim 8, wherein the expansion is in the presence of an anti-CD28 antibody and IL-12.

### Claim 12

A pharmaceutical composition comprising a peptide consisting of the amino acid sequence selected from SEQ ID NOs: 45, 46, 6, 1-5, 7-29, 31-44, 47-80, 82-98, and 100-161 in the form of a pharmaceutically acceptable salt and an immune-stimulating adjuvant.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein the pharmaceutically acceptable salt is chloride salt.

### Claim 14 (depends on 12)

The pharmaceutical composition of claim 12, wherein the pharmaceutically acceptable salt is acetate salt.

### Claim 15 (depends on 12)

The pharmaceutical composition of claim 12, wherein the adjuvant is selected from anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

### Claim 16 (depends on 12)

The pharmaceutical composition of claim 12, wherein the adjuvant comprises IL-2.

### Claim 17 (depends on 12)

The pharmaceutical composition of claim 12, wherein the adjuvant comprises IL-7.

### Claim 18 (depends on 12)

The pharmaceutical composition of claim 12, wherein the adjuvant comprises IL-15.

### Claim 19 (depends on 12)

The pharmaceutical composition of claim 12, wherein the adjuvant comprises IL-21.

### Claim 20 (depends on 12)

The pharmaceutical composition of claim 12, wherein the adjuvant comprises cyclophosphamide.